RD06-05

N/A

Report date: 2026/05/20 20:02:01

Base Information

Drug NameRD06-05
Drug Alias Nameallogenic anti-CD19/BCMA CAR-TRD06-05
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionB-lymphocyte antigen CD19 modulatorsT lymphocyte replacementsB-cell maturation protein modulators
TargetsB-lymphocyte antigen CD19B-cell maturation protein
Therapy Area/IndicationsEvans syndromeScleroderma, SystemicLupus Erythematosus, Systemic +[17] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesNanjing Bioheng Biotech Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesNanjing Bioheng Biotech Co LtdShanghai Zhongshan Hospital
Inactive CompaniesN/A
Active IndicationsEvans syndromeScleroderma, SystemicLupus Erythematosus, Systemic +[17] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A